Skip to main content
Erschienen in: Drugs 5/2018

01.04.2018 | Review Article

Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management

verfasst von: Sebastiano Mercadante

Erschienen in: Drugs | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this review is to present the way in which episodic breathlessness (EB) has been recognized over the years, with regard to definition, characteristics, and management of these acute episodes that have serious consequences for patients. EB is characterized by a sudden increase in intensity of dyspnea over a short duration of time, leading to high levels of anxiety. A significant aggravation of dyspnea may occur in patients with a background of dyspnea or intermittently even without basal breathlessness. Often, known precipitating factors may trigger EB. Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB. In any case, there is a reinforcing circuit. The duration of EB ranges from 10–30 min. Given the specific temporal pattern, requiring rapid intervention, substances with a short onset of action are suitable to overlap this phenomenon. Short-onset opioids could provide a clinical effect overlapping the onset and duration of an episode, resembling what has been largely reported for breakthrough pain. Although data are still insufficient to suggest specific recommendations, strategies such as avoiding exertion, pacing or using devices, or keeping calm have been described. Few controlled studies have investigated the effects of different formulations of opioids. Some data were gathered from studies assessing the pre-emptive use of rapid onset opioids, such as transmucosal preparations of fentanyl, followed by a provocative test, while other studies attempted to reproduce real-life conditions, given as needed. All these trials were insufficiently powered to address the efficacy of fentanyl products over oral morphine or placebo, reflecting the difficulties in patient recruiting and finalizing the studies. Strategies to prevent the occurrence of EB should be taken into consideration, including optimization of the condition of persistent dyspnea or treating psychologic or environmental causes.
Literatur
1.
Zurück zum Zitat Vainio A, Auvinen A. prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manag. 1996;12:3–10.CrossRef Vainio A, Auvinen A. prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manag. 1996;12:3–10.CrossRef
2.
Zurück zum Zitat Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manag. 2001;21:92–5.CrossRef Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manag. 2001;21:92–5.CrossRef
3.
Zurück zum Zitat Barbera L, Seow H, Howell D, et al. Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer. 2010;116:5767–76.CrossRefPubMed Barbera L, Seow H, Howell D, et al. Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer. 2010;116:5767–76.CrossRefPubMed
4.
Zurück zum Zitat Reddy SK, Parsons HA, Elsayem A, Palmer JL, Bruera E. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med. 2009;12:29–36.CrossRefPubMed Reddy SK, Parsons HA, Elsayem A, Palmer JL, Bruera E. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med. 2009;12:29–36.CrossRefPubMed
5.
Zurück zum Zitat Currow DC, Higginson IJ, Johnson MJ. Breathlessness. Current and emerging mechanisms, measurement and management. A discussion from an European Association of Palliative Care workshop. Palliat Med. 2013;27:932–8.CrossRefPubMed Currow DC, Higginson IJ, Johnson MJ. Breathlessness. Current and emerging mechanisms, measurement and management. A discussion from an European Association of Palliative Care workshop. Palliat Med. 2013;27:932–8.CrossRefPubMed
6.
Zurück zum Zitat Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manag. 2000;20:104–12.CrossRef Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manag. 2000;20:104–12.CrossRef
7.
Zurück zum Zitat Escalante CP, Martin CG, Elting LS, et al. Identifying risk factors for imminent death in cancer patients with acute dyspnea. J Pain Symptom Manag. 2000;20:318–25.CrossRef Escalante CP, Martin CG, Elting LS, et al. Identifying risk factors for imminent death in cancer patients with acute dyspnea. J Pain Symptom Manag. 2000;20:318–25.CrossRef
8.
Zurück zum Zitat Simon ST, Higginson IJ, Benalia HH, et al. Episodic and continuous breathlessness: a new categorization of breathlessness. J Pain Symptom Manag. 2013;45:1019–29.CrossRef Simon ST, Higginson IJ, Benalia HH, et al. Episodic and continuous breathlessness: a new categorization of breathlessness. J Pain Symptom Manag. 2013;45:1019–29.CrossRef
9.
Zurück zum Zitat Parshall MB, Schwartzstein RM, Adams L, American Thoracic Society Committee on Dyspnea, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–52.CrossRefPubMedPubMedCentral Parshall MB, Schwartzstein RM, Adams L, American Thoracic Society Committee on Dyspnea, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–52.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Mercadante S, Marchetti P, Cuomo A, Mammucari M, Caraceni A, IOPS MS study Group. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer. 2016;24:961–8.CrossRefPubMed Mercadante S, Marchetti P, Cuomo A, Mammucari M, Caraceni A, IOPS MS study Group. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer. 2016;24:961–8.CrossRefPubMed
11.
Zurück zum Zitat Mercadante S, Porzio G, Valle A, et al. Emergencies in patients with advanced cancer followed at home. J Pain Symptom Manag. 2012;44:295–300.CrossRef Mercadante S, Porzio G, Valle A, et al. Emergencies in patients with advanced cancer followed at home. J Pain Symptom Manag. 2012;44:295–300.CrossRef
12.
Zurück zum Zitat Simon ST, Higginson IJ, Benalia H, et al. Episodes of breathlessness: types and patterns—a qualitative study exploring experiences of patients with advanced diseases. Palliat Med. 2013;27:524–32.CrossRefPubMed Simon ST, Higginson IJ, Benalia H, et al. Episodes of breathlessness: types and patterns—a qualitative study exploring experiences of patients with advanced diseases. Palliat Med. 2013;27:524–32.CrossRefPubMed
13.
Zurück zum Zitat Spathis A, Booth C, Hurst R, et al. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim Care Respir Med. 2017;27(1):27.CrossRefPubMedPubMedCentral Spathis A, Booth C, Hurst R, et al. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim Care Respir Med. 2017;27(1):27.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3:CD011008.PubMed Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3:CD011008.PubMed
15.
Zurück zum Zitat Weingartner V, Scheve C, Gerdes V, et al. Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: results of a descriptive cohort study. Palliat Med. 2015;29:420–8.CrossRefPubMed Weingartner V, Scheve C, Gerdes V, et al. Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: results of a descriptive cohort study. Palliat Med. 2015;29:420–8.CrossRefPubMed
16.
Zurück zum Zitat Simon ST, Bausewein C, Schildmann E, et al. Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manag. 2013;45:561–78.CrossRef Simon ST, Bausewein C, Schildmann E, et al. Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manag. 2013;45:561–78.CrossRef
17.
Zurück zum Zitat Mercadante S, Aielli F, Adile C, et al. Epidemiology and characteristics of episodic breathlessness in advanced cancer patients: an observational study. J Pain Symptom Manag. 2016;51:17–24.CrossRef Mercadante S, Aielli F, Adile C, et al. Epidemiology and characteristics of episodic breathlessness in advanced cancer patients: an observational study. J Pain Symptom Manag. 2016;51:17–24.CrossRef
18.
Zurück zum Zitat Mercadante S, Fusco F, Caruselli A, et al. Background and episodic breathlessness in advanced cancer patients followed at home. Curr Med Res Opin. 2017;33:155–60.CrossRefPubMed Mercadante S, Fusco F, Caruselli A, et al. Background and episodic breathlessness in advanced cancer patients followed at home. Curr Med Res Opin. 2017;33:155–60.CrossRefPubMed
19.
Zurück zum Zitat Simon ST, Weingartner V, Higginson IJ, et al. “I Can Breath Again!” Patients’ self-management strategies for episodic breathlessness in advanced disease, derived from qualitative interviews. J Pain Symptom Manag. 2016;52:228–34.CrossRef Simon ST, Weingartner V, Higginson IJ, et al. “I Can Breath Again!” Patients’ self-management strategies for episodic breathlessness in advanced disease, derived from qualitative interviews. J Pain Symptom Manag. 2016;52:228–34.CrossRef
20.
21.
Zurück zum Zitat Zhao I, Yates P. Non-pharmacological interventions for breathlessness management in patients with lung cancer: a systematic review. Palliat Med. 2008;22:693–701.CrossRefPubMed Zhao I, Yates P. Non-pharmacological interventions for breathlessness management in patients with lung cancer: a systematic review. Palliat Med. 2008;22:693–701.CrossRefPubMed
22.
Zurück zum Zitat Gauna AA, Kang SK, Lawhon Triano M, Swatcho ER, Vanston VJ. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. J Palliat Med. 2008;11:643–8.CrossRefPubMed Gauna AA, Kang SK, Lawhon Triano M, Swatcho ER, Vanston VJ. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. J Palliat Med. 2008;11:643–8.CrossRefPubMed
23.
Zurück zum Zitat Benitez-Rosario MA, Martin AS, Feria M. Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients. J Pain Symptom Manag. 2005;30:395–7.CrossRef Benitez-Rosario MA, Martin AS, Feria M. Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients. J Pain Symptom Manag. 2005;30:395–7.CrossRef
24.
Zurück zum Zitat Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manag. 2008;36:29–38.CrossRef Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manag. 2008;36:29–38.CrossRef
25.
Zurück zum Zitat Hui D, Xu A, Frisbee-Hume S, Chisholm G, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manag. 2014;47:209–27.CrossRef Hui D, Xu A, Frisbee-Hume S, Chisholm G, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manag. 2014;47:209–27.CrossRef
26.
Zurück zum Zitat Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28:963–8.CrossRefPubMed Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28:963–8.CrossRefPubMed
27.
Zurück zum Zitat Pinna MA, Bruera E, Moralo MJ, Correas MA, Vargas RM. A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. Am J Hosp Palliat Care. 2015;32:298–304.CrossRefPubMed Pinna MA, Bruera E, Moralo MJ, Correas MA, Vargas RM. A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. Am J Hosp Palliat Care. 2015;32:298–304.CrossRefPubMed
28.
Zurück zum Zitat Hui D, Kilgore K, Park M, et al. Impact of prophylactic fentanyl pectin nasal spray on exercise-induced episodic dyspnea in cancer patients: a double-blind, randomized controlled trial. J Pain Symptom Manag. 2016;52:459–68.CrossRef Hui D, Kilgore K, Park M, et al. Impact of prophylactic fentanyl pectin nasal spray on exercise-induced episodic dyspnea in cancer patients: a double-blind, randomized controlled trial. J Pain Symptom Manag. 2016;52:459–68.CrossRef
29.
Zurück zum Zitat Hui D, Kilgore K, Frisbee-Hume S, et al. Effect of prophylactic fentanyl buccal tablet on episodic exertional dyspnea: a pilot double-blind randomized controlled trial. J Pain Symptom Manag. 2017;54:798–805.CrossRef Hui D, Kilgore K, Frisbee-Hume S, et al. Effect of prophylactic fentanyl buccal tablet on episodic exertional dyspnea: a pilot double-blind randomized controlled trial. J Pain Symptom Manag. 2017;54:798–805.CrossRef
30.
Zurück zum Zitat Simon ST, Kloke M, Alt-Epping B, et al. EffenDys-fentanyl buccal tablet for the relief of episodic breathlessness in patients with advanced cancer: a multicenter, open-label, randomized, morphine-controlled, crossover, phase II trial. J Pain Symptom Manag. 2016;52:617–25.CrossRef Simon ST, Kloke M, Alt-Epping B, et al. EffenDys-fentanyl buccal tablet for the relief of episodic breathlessness in patients with advanced cancer: a multicenter, open-label, randomized, morphine-controlled, crossover, phase II trial. J Pain Symptom Manag. 2016;52:617–25.CrossRef
Metadaten
Titel
Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management
verfasst von
Sebastiano Mercadante
Publikationsdatum
01.04.2018
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2018
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0879-5

Weitere Artikel der Ausgabe 5/2018

Drugs 5/2018 Zur Ausgabe